#Denmark #Copenhagen #Hedia #Rasmus Kofoed #Lars Christian Lund

Hedia Appoints Rasmus Kofoed as New CEO

In a significant leadership change, Hedia, a prominent Danish company specializing in diabetes technology, has announced that Rasmus Kofoed will succeed Lars Christian Lund as the Chief Executive Officer (CEO) as of December 1, 2025. This decision marks a pivotal moment for the company as it continues to strengthen its position in the digital diabetes management industry.

Transitioning Leadership

Lars Christian Lund, who has been at the helm for around two years, will step down to take on the role of Group CEO at another international firm. His tenure was marked by notable achievements, including the transition of Hedia from a budding startup to a well-established scale-up with regulatory and commercial advancements. Under his leadership, Hedia secured regulatory approvals and laid the groundwork for future global growth.

Carl Bilbo, Hedia's Chairman, expressed gratitude for Lund's contributions, highlighting his pivotal role in enhancing organizational strength and achieving medical device regulation (MDR) compliance. Bilbo referred to Kofoed as the right choice to guide Hedia through its next growth phase, emphasizing his strategic and commercial expertise in life sciences and medtech.

Rasmus Kofoed's Vision for Hedia

Rasmus Kofoed comes to Hedia with an impressive track record, having held senior roles at esteemed companies like Novo Nordisk, Abbott, Roche, and Medtronic. He has also served as CEO of ChemoMetec, where he was responsible for significant commercial and strategic initiatives, including international expansion and transformative growth strategies.

Upon his appointment, Kofoed voiced his enthusiasm about the potential of Hedia. He stated, "The company combines clinical insight with technology in a way that creates real value for people with diabetes. I look forward to collaborating with the team to broaden our reach, strengthen our partnerships, and enhance our journey towards becoming a leading force in digital diabetes care."

Hedia's Future Direction

As Kofoed prepares to take charge, he aims to expand Hedia's product lines and refine its market strategies with a strong focus on enhancing international partnerships. This leadership change signifies more than just a new name at the top; it represents Hedia's commitment to continuous growth in the digital health sector and an unwavering dedication to improving the lives of those managing insulin-dependent diabetes.

Since its inception in 2016, Hedia has established itself within European markets as a pioneer in digital diabetes management. The company's innovative solutions harness the power of data, artificial intelligence, and accessible app technology to support users in managing their treatment effectively. Kofoed's leadership will likely propel Hedia into new heights, marking a promising chapter in its business narrative.

With Kofoed at the helm, stakeholders are optimistic about the potential expansion of Hedia's influence and contributions in the field of diabetes technology, challenging the status quo and pioneering solutions that empower patients through technology. As the company looks towards the horizon, it is set to enhance not only its operational capabilities but also its collective commitment to improving health outcomes for diabetes patients across the globe.